Abstract #0700
Manganese-Enhanced MRI for Preclinical Evaluation of Therapeutic Efficacy of Retinal Degeneration Treatment
Rebecca M Schur 1 , Li Sheng 1 , Bhubanananda Sahu 2 , Guanping Yu 1 , Song-Qi Gao 3 , Xin Yu 1 , Akiko Maeda 2 , Krzysztof Palczewski 3 , and Zheng-Rong Lu 1
1
Biomedical Engineering, Case Western Reserve
University, Cleveland, OH, United States,
2
Ophthamology
and Visual Sciences, Case Western Reserve University,
Cleveland, OH, United States,
3
Pharmacology,
Case Western Reserve University, Cleveland, OH, United
States
Numerous therapies to treat degenerative retinal
diseases are currently in preclinical development. To
evaluate therapeutic efficacy of these drugs, a
manganese-enhanced MRI (MEMRI) protocol was implemented
to simultaneously evaluate both structure and function
of retinas of treated mice. Following intravitreous
injection of MnCl2, signal enhancement was measured in
the retinas of healthy and treated animals, while in
light-induced blinded animals, signal in the retina
remained unchanged. Results were consistent with
standard OCT, histology, and ERG methods. This work
suggests that MEMRI is a promising alternative technique
to evaluate therapeutic efficacy of retinopathy drugs
during preclinical development.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
